公开(公告)号：US12144785B2

公开(公告)日：2024-11-19

申请号：US15151970

申请日：2016-05-11

Applicant: NATTOPHARMA AS

Inventor： Cees Vermeer

IPC: A61K31/122 ,  A23L2/52 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A61K31/12 ,  A61K31/59 ,  A61K31/593 ,  A61K45/06 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14

Abstract: Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg's sclerosis and stroke. In various embodiments, vitamin K can also be used to reduce or reverse calcification of a blood vessel in pre-existing cardiovascular disorders such as arteriosclerosis.

公开(公告)号：US12128056B2

公开(公告)日：2024-10-29

申请号：US17365949

申请日：2021-07-01

Applicant: Natals, Inc.

Inventor： Luke Bucci ,  Katerina Schneider ,  Mastaneh Sharafi ,  Nima Alamdari

IPC: A61K31/593 ,  A23D9/007 ,  A23L5/00 ,  A23L33/00 ,  A23L33/115 ,  A23L33/12 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A61K9/16 ,  A61K9/48 ,  A61K31/122 ,  A61K31/202 ,  A61K31/355 ,  A61K31/519 ,  A61K31/714 ,  A61K33/06 ,  A61K33/22 ,  A61K33/26 ,  A61K36/02 ,  A61K36/31 ,  B65D25/54 ,  B65D81/20

CPC classification number: A61K31/593 ,  A23D9/007 ,  A23L5/00 ,  A23L33/115 ,  A23L33/12 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23L33/40 ,  A61K9/1652 ,  A61K9/1664 ,  A61K9/1676 ,  A61K9/4808 ,  A61K31/122 ,  A61K31/202 ,  A61K31/355 ,  A61K31/519 ,  A61K31/714 ,  A61K33/06 ,  A61K33/22 ,  A61K33/26 ,  A61K36/02 ,  A61K36/31 ,  B65D25/54 ,  B65D81/2076 ,  A23V2002/00 ,  B65D2203/12 ,  A23V2002/00 ,  A23V2200/224 ,  A23V2200/30 ,  A23V2250/1572 ,  A23V2250/1592 ,  A23V2250/161 ,  A23V2250/1642 ,  A23V2250/1882 ,  A23V2250/202 ,  A23V2250/5054 ,  A23V2250/51084 ,  A23V2250/702 ,  A23V2250/7056 ,  A23V2250/706 ,  A23V2250/71 ,  A23V2250/712 ,  A23V2250/714 ,  A23V2002/00 ,  A23V2200/224 ,  A23V2200/30 ,  A23V2250/1572 ,  A23V2250/1592 ,  A23V2250/161 ,  A23V2250/1882 ,  A23V2250/202 ,  A23V2250/5054 ,  A23V2250/51084 ,  A23V2250/7056 ,  A23V2250/706 ,  A23V2250/71 ,  A23V2250/712 ,  A23V2250/714

Abstract: Provided herein are dietary supplement compositions comprising a plurality of beadlets and an oil. Provided herein are also dietary supplement compositions comprising a plurality of mini-tabs and oil. The beadlets or mini-tabs comprise at least one nutrient that is miscible in aqueous solution, and the oil comprises at least one fat-soluble nutrient. The composition may be contained within one or more capsules, and be packaged with a scented insert.

公开(公告)号：US12082600B2

公开(公告)日：2024-09-10

申请号：US17152600

申请日：2021-01-19

Applicant: CSM BAKERY SOLUTIONS EUROPE HOLDING B.V.

Inventor： Mattanja Metz-Dees ,  Rob Sikking

IPC: A23L29/00 ,  A23C11/10 ,  A23L2/52 ,  A23L11/65 ,  A23L33/00 ,  A23L33/155

CPC classification number: A23L29/035 ,  A23C11/103 ,  A23C11/106 ,  A23L2/52 ,  A23L11/65 ,  A23L33/155 ,  A23L33/30

Abstract: A concentrated calcium citrate suspension is disclosed, comprising: (a) 2.0-9.0 wt. % of high methoxy pectin; (b) 2.5-7.0 wt. % tricalcium citrate particles; (c) dissolved citrate in a concentration of 1.8-7.0 wt. % citric acid equivalent; (d) 0.7-2.1 mol alkali metal cation per mol of dissolved citrate, with the alkali metal cation being selected from Na+, K+ and combinations thereof; and (e) 78-90 wt. % water. The concentrated calcium citrate suspension is shelf-stable, easy to handle and has a high content of (undissolved) calcium citrate. The concentrated calcium citrate suspension is particularly suited for use in the production of calcium-fortified soy protein based alternatives for dairy products.

公开(公告)号：US20240285704A1

公开(公告)日：2024-08-29

申请号：US18406671

申请日：2024-01-08

Applicant: FP Nutraceuticals, LLC

Inventor： Timothy M. Marshall

IPC: A61K36/185 ,  A23L33/105 ,  A23L33/115 ,  A23L33/125 ,  A23L33/155 ,  A23L33/16 ,  A23L33/165 ,  A23L33/175 ,  A61K9/00 ,  A61K31/015 ,  A61K31/05 ,  A61K31/07 ,  A61K31/122 ,  A61K31/145 ,  A61K31/16 ,  A61K31/192 ,  A61K31/194 ,  A61K31/198 ,  A61K31/232 ,  A61K31/28 ,  A61K31/30 ,  A61K31/315 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/525 ,  A61K31/592 ,  A61K31/593 ,  A61K31/675 ,  A61K31/69 ,  A61K31/714 ,  A61K33/06 ,  A61K33/18 ,  A61K36/03 ,  A61K36/42 ,  A61K36/45

CPC classification number: A61K36/185 ,  A23L33/105 ,  A23L33/115 ,  A23L33/125 ,  A23L33/155 ,  A23L33/16 ,  A23L33/165 ,  A23L33/175 ,  A61K9/0056 ,  A61K31/015 ,  A61K31/05 ,  A61K31/07 ,  A61K31/122 ,  A61K31/145 ,  A61K31/16 ,  A61K31/192 ,  A61K31/194 ,  A61K31/198 ,  A61K31/232 ,  A61K31/28 ,  A61K31/30 ,  A61K31/315 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/525 ,  A61K31/592 ,  A61K31/593 ,  A61K31/675 ,  A61K31/69 ,  A61K31/714 ,  A61K33/06 ,  A61K33/18 ,  A61K36/03 ,  A61K36/42 ,  A61K36/45 ,  A23V2002/00

Abstract: The compositions of this disclosure provide broad-spectrum nutrient supplementation to support the health of multiple organ and tissue systems in which mitochondrial function plays a fundamental role. In particular, the formulations promote neuroprotective, cardioprotective, immunosupportive, and anti-aging benefits. Also provided herein are novel, neuroprotective preparations containing a combination of broad- or full-spectrum hemp oil extract combined with niacinamide, a non-flushing form of vitamin B3, and methods of use are described allowing for safe, effective, and convenient use of a neuroprotective, antioxidant preparation for general and clinical use.

公开(公告)号：US12005096B2

公开(公告)日：2024-06-11

申请号：US17119075

申请日：2020-12-11

Applicant: QUINCY BIOSCIENCE, LLC

Inventor： Mark Y. Underwood

IPC: A61K38/17 ,  A23L33/155 ,  A23L33/17 ,  A61K9/48 ,  A61K31/593

CPC classification number: A61K38/1767 ,  A23L33/155 ,  A23L33/17 ,  A61K9/48 ,  A61K31/593

Abstract: Compositions containing apoaequorin and vitamin D and methods for their use in treating symptoms and disorders related to calcium imbalances and vitamin D deficiency associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention.

公开(公告)号：US11937625B2

公开(公告)日：2024-03-26

申请号：US16954401

申请日：2018-12-18

Applicant: CENTRO DE RETINA MEDICA Y QUIRURGICA, S.C.

Inventor： Arturo Santos Garcia ,  Juan Carlos Altamirano Vallejo ,  Jose Alonso Chavez Garcia ,  Alejandro Gonzalez De La Rosa

IPC: A23L33/19 ,  A23L33/105 ,  A23L33/12 ,  A23L33/155

CPC classification number: A23L33/19 ,  A23L33/105 ,  A23L33/12 ,  A23L33/155

Abstract: The invention relates to a nutraceutical formulation of blueberry extract, fish oil (omega-3 and omega-6), recombinant human lactoferrin, vitamin A and vitamin E, for human oral consumption. The invention belongs to the field of ophthalmology and has been developed as a coadjuvant for preserving the health of the precorneal film and of the eye surface. This formulation contains an extract of natural origin (Vaccinium myrtillus L) with antioxidant and anti-inflammatory properties; it also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, improves tear quality, since these compounds have anti-microbial and anti-inflammatory effects. This formulation has been designed as a coadjuvant for preserving the health of the precorneal film. No formulation for oral administration of a blueberry extract together with lactoferrin, in combination with vitamin A, vitamin E and fish oil (eicosapentaenoic acid and docosahexaenoic acid) is found in the prior art, nor is the use of this formulation as an adjuvant for preserving the health of the precorneal film and/or the eye surface.

公开(公告)号：US20240065996A1

公开(公告)日：2024-02-29

申请号：US18387738

申请日：2023-11-07

Applicant: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.

Inventor： Jill Hamilton-Reeves ,  Jeffrey M. Holzbeierlein ,  Thomas Yankee

IPC: A61K31/198 ,  A23L33/00 ,  A23L33/12 ,  A23L33/13 ,  A23L33/14 ,  A23L33/155 ,  A23L33/175 ,  A61K9/00 ,  A61K31/07 ,  A61K31/202 ,  A61K31/70 ,  A61K31/7088

CPC classification number: A61K31/198 ,  A23L33/12 ,  A23L33/13 ,  A23L33/14 ,  A23L33/155 ,  A23L33/175 ,  A23L33/30 ,  A61K9/0053 ,  A61K9/0095 ,  A61K31/07 ,  A61K31/202 ,  A61K31/70 ,  A61K31/7088 ,  A23V2002/00

Abstract: A specialized immunonutrition supplement can be administered to a surgical patient to reduce post-operative complications by restraining the expansion of myeloid-derived suppressor cells. The supplement includes one or more of L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides, preferably all four of these compounds. The supplement is administered to the patient at least once per day for a time period extending from a pre-operative day that is three to seven days prior to a bladder surgery of the patient to a post-operative day that is three to seven days after the bladder surgery. The supplement can be administered to treat or prevent post-operative paralytic ileus in a bladder cancer patient; treat or prevent surgery-induced, inflammation-induced or cancer-induced cachexia; reduce the incidence of chronic infections resulting from expansion of myeloid-derived suppressor cells in a patient; and/or reduce mRNA expression of pro-inflammatory cytokines in a patient.

公开(公告)号：US20240024386A1

公开(公告)日：2024-01-25

申请号：US18018178

申请日：2021-07-27

Applicant: INFINANT HEALTH, INC.

Inventor： David KYLE ,  Bethany HENRICK

IPC: A61K35/747 ,  A61K45/06 ,  A61K35/745 ,  A61K47/14 ,  A61K31/702 ,  A61K31/202 ,  A61K31/07 ,  A61K31/375 ,  A61P37/04 ,  A61K47/44 ,  A23L33/12 ,  A23L33/155 ,  A23L33/135 ,  A23L33/00 ,  A23L33/125

CPC classification number: A61K35/747 ,  A61K45/06 ,  A61K35/745 ,  A61K47/14 ,  A61K31/702 ,  A61K31/202 ,  A61K31/07 ,  A61K31/375 ,  A61P37/04 ,  A61K47/44 ,  A23L33/12 ,  A23L33/155 ,  A23L33/135 ,  A23L33/40 ,  A23L33/125

Abstract: The invention described herein relates generally to methods and compositions for administration to modulate the microbiome for the express purpose of increasing host interferon beta (IPNβ) in mammals of target populations that are at risk for or are being treated for certain inflammatory conditions including infections, viral infection, autoimmune conditions, and recovery from sequalae associated with acute inflammatory insults. In particular, the invention provides a method of elevating the level of IPNβ in the gut of a mammal by providing the mammal with a live bacterium and a prebiotic that the live bacterium is known to consume. Further, the invention described herein may relate to the administration of compositions found to increase the endogenous production of IPNβ in the target mammal.

公开(公告)号：US11857525B2

公开(公告)日：2024-01-02

申请号：US15548186

申请日：2016-02-15

Applicant: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.

Inventor： Jill Hamilton-Reeves ,  Jeffrey M. Holzbeierlein ,  Thomas Yankee

IPC: A61K31/198 ,  A61K31/07 ,  A61K31/202 ,  A61K31/70 ,  A23L33/12 ,  A23L33/13 ,  A23L33/14 ,  A23L33/00 ,  A23L33/175 ,  A23L33/155 ,  A61K9/00 ,  A61K31/7088

CPC classification number: A61K31/198 ,  A23L33/12 ,  A23L33/13 ,  A23L33/14 ,  A23L33/155 ,  A23L33/175 ,  A23L33/30 ,  A61K9/0053 ,  A61K9/0095 ,  A61K31/07 ,  A61K31/202 ,  A61K31/70 ,  A61K31/7088 ,  A23V2002/00

Abstract: A specialized immunonutrition supplement can be administered to a surgical patient to reduce post-operative complications by restraining the expansion of myeloid-derived suppressor cells. The supplement includes one or more of L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides, preferably all four of these compounds. The supplement is administered to the patient at least once per day for a time period extending from a pre-operative day that is three to seven days prior to a bladder surgery of the patient to a post-operative day that is three to seven days after the bladder surgery. The supplement can be administered to treat or prevent post-operative paralytic ileus in a bladder cancer patient; treat or prevent surgery-induced, inflammation-induced or cancer-induced cachexia; reduce the incidence of chronic infections resulting from expansion of myeloid-derived suppressor cells in a patient; and/or reduce mRNA expression of pro-inflammatory cytokines in a patient.

公开(公告)号：US20230365313A1

公开(公告)日：2023-11-16

申请号：US18195761

申请日：2023-05-10

Applicant: Kate Farms, Inc.

Inventor： Maia C. Vernacchia ,  Vanessa Laura Millovich ,  Joseph T. Rupnow ,  Dwan Charissa Newman ,  Erin C. Lamb ,  Zhaozhi Huang

IPC: B65D75/00 ,  A23L33/12 ,  A23L33/22 ,  A23L33/155 ,  A23L33/15 ,  A23L33/16 ,  A23L33/185 ,  A23L33/105 ,  B65D41/04 ,  B65D75/58 ,  A61K31/202 ,  A61K36/899 ,  A61K36/70 ,  A61K38/16 ,  A61K33/42 ,  A61K31/14 ,  A61K33/10 ,  A61K31/375 ,  A61K33/14 ,  A61K31/015 ,  A61K31/197 ,  A61K31/593 ,  A61K31/355 ,  A61K31/07 ,  A61K31/4188 ,  A61K31/555 ,  A61K33/34 ,  A61K31/714 ,  A61K31/4738 ,  A61K33/32 ,  A61K31/455 ,  A61K31/122 ,  A61K33/18 ,  A61K31/4415 ,  A61K31/525 ,  A61K33/00 ,  A61K33/04 ,  A61K31/51 ,  A61K31/7004 ,  A61K31/198 ,  A61K31/405 ,  A61K36/73 ,  A61K36/21 ,  A61K36/31 ,  A61K36/45 ,  A61K36/42 ,  A61K36/23 ,  A61K36/48 ,  A61K36/8945 ,  A61K36/88 ,  A61K36/22 ,  A61K36/54 ,  A61K36/906 ,  A61K36/53 ,  A61K31/23 ,  A61K31/145

CPC classification number: B65D75/008 ,  A23L33/12 ,  A23L33/22 ,  A23L33/155 ,  A23L33/15 ,  A23L33/16 ,  A23L33/185 ,  A23L33/105 ,  B65D41/04 ,  B65D75/5883 ,  A61K31/202 ,  A61K36/899 ,  A61K36/70 ,  A61K38/168 ,  A61K33/42 ,  A61K31/14 ,  A61K33/10 ,  A61K31/375 ,  A61K33/14 ,  A61K31/015 ,  A61K31/197 ,  A61K31/593 ,  A61K31/355 ,  A61K31/07 ,  A61K31/4188 ,  A61K31/555 ,  A61K33/34 ,  A61K31/714 ,  A61K31/4738 ,  A61K33/32 ,  A61K31/455 ,  A61K31/122 ,  A61K33/18 ,  A61K31/4415 ,  A61K31/525 ,  A61K33/00 ,  A61K33/04 ,  A61K31/51 ,  A61K31/7004 ,  A61K31/198 ,  A61K31/405 ,  A61K36/73 ,  A61K36/21 ,  A61K36/31 ,  A61K36/45 ,  A61K36/42 ,  A61K36/23 ,  A61K36/48 ,  A61K36/8945 ,  A61K36/88 ,  A61K36/22 ,  A61K36/54 ,  A61K36/906 ,  A61K36/53 ,  A61K31/23 ,  A61K31/145 ,  B65D2207/00 ,  B65D2575/586

Abstract: A bag system for containing a nutritional composition includes a pouch for holding a nutritional composition front and rear panels which are welded to each other by a bottom weld and a top weld and two welds on each opposed side; and a port for filling and. dispensing for feeding at the top of the pouch with a cap/lid to be resealable. An 8 French tube or larger is connected at the port for delivering the composition without dilution and via enteral pump delivery, A nutritional composition has fatty acids; dietary fibers; carbohydrates; a vitamin and mineral blend; proteins; and a whole food blend. A nutritionally complete nutrient composition for enteral feeding comprises a whole food blend and additional nutrients. Preferably; the nutrient composition is provided in a squeezable serving pouch. The nutrient composition is free of major allergens.